Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 4/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | CKS1B | P61024 | 2/20 | 0.44 |
| ▸ | SKP1 | P63208 | 2/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496529 | 0.82 | OPRL1 (0.48) | PRMT5OPRL1OPRM1OPRK1KCNH2 | |
| SCHEMBL18163251 | 0.80 | PRMT5 (0.58) | PRMT5MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL18163226 | 0.78 | PRMT5 (0.56) | PRMT5MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL6477715 | 0.74 | PRMT5 (0.69) | PRMT5MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL18163277 | 0.74 | MAP4K4 (0.54) | PRMT5MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL18163222 | 0.74 | MAP4K4 (0.52) | PRMT5MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL18163292 | 0.72 | PDE3B (0.52) | PRMT5MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL6485481 | 0.71 | MAP4K4 (0.53) | PRMT5MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL16249702 | 0.71 | MAP4K4 (0.55) | PRMT5MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL461584 | 0.70 | CKS1B (0.62) | MAP4K4CKS1BSKP1SKP2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044056-A1 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044056-A1 | Benzimidazole derivatives | GPR119, OPRL1, INSR | PRMT5 1345/4885MAP4K4 1567/4885CKS1B 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.